ReviewOncology reviews2026
Non-coding RNAs as predictive factors of oncological outcomes in plasma cell myeloma.
Review in Oncology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma cell myeloma (PCM) is the second most common haematological malignancy and accounts for 1% of all hematological tumors. PCM remains a challenging disease to treat because of its heterogeneity. Despite therapeutic advances, a significant proportion of patients do not respond to treatment or develop resistance, highlighting the need to identify reliable predictive biomarkers. Recent research suggests that non-coding RNAs (ncRNAs), i.e., microRNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA) are important regulators of gene expression and play a key role in the pathogenesis. Epigenetic changes precede genetic and protein modifications, and the analysis of a single ncRNA can reflect the status of several genes. Moreover, ncRNAs are stable and can be detected in a minimally invasive manner using readily available biological samples. This review synthesizes current preclinical and clinical data on ncRNAs as predictive biomarkers of response to PCM therapies, identifies the most promising molecules and their mechanisms of action, highlights key methodological limitations, and proposes a translational validation framework necessary for clinical implementation. The most promising candidates are miR-21, lncRNA: MALAT1, and PCAT-1, which are well established in the literature and confirmed at both the mechanistic and clinical levels. However, small cohorts, heterogeneity of studies, and lack of methodological standardization limit the strength of this evidence, highlighting the need for prospective multicenter studies with standardized analytical procedures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.